within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01F_MacrolidesLincosamidesAndStreptogramins.J01FF02_Lincomycin;

model Lincomycin
  extends Pharmacolibrary.Drugs.ATC.J.J01FF02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01FF02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lincomycin is an antibiotic in the lincosamide class, used primarily for the treatment of serious infections caused by susceptible strains of streptococci, pneumococci, and staphylococci. It was historically used for severe infections in patients allergic to penicillin, but has largely been replaced by clindamycin in clinical practice. It is FDA approved but not widely used today due to better alternatives.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics described for adult healthy subjects after intravenous administration.</p><h4>References</h4><ol><li><p>Sreeshitha Gouri, S, et al., &amp; Dumka, VK (2014). Pharmacokinetics of lincomycin following single intravenous administration in buffalo calves. <i>Tropical animal health and production</i> 46(6) 1099–1102. DOI:<a href=\"https://doi.org/10.1007/s11250-014-0595-4\">10.1007/s11250-014-0595-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24792222/\">https://pubmed.ncbi.nlm.nih.gov/24792222</a></p></li><li><p>Albarellos, GA, et al., &amp; Landoni, MF (2012). Pharmacokinetics and bone tissue concentrations of lincomycin following intravenous and intramuscular administrations to cats. <i>Journal of veterinary pharmacology and therapeutics</i> 35(6) 534–540. DOI:<a href=\"https://doi.org/10.1111/j.1365-2885.2011.01355.x\">10.1111/j.1365-2885.2011.01355.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22132730/\">https://pubmed.ncbi.nlm.nih.gov/22132730</a></p></li><li><p>Watson, MK, et al., &amp; Chinnadurai, SK (2017). Pharmacokinetics of intravenous clindamycin phosphate in captive Bennett&#x27;s wallabies (Macropus rufogriseus). <i>Journal of veterinary pharmacology and therapeutics</i> 40(6) 682–686. DOI:<a href=\"https://doi.org/10.1111/jvp.12421\">10.1111/jvp.12421</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28568310/\">https://pubmed.ncbi.nlm.nih.gov/28568310</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Lincomycin;
